Mentor Injects Dermal Filler Pipeline With Genzyme R&D
This article was originally published in The Gray Sheet
Executive Summary
Mentor will market future Genzyme-developed hyaluronic acid dermal filler products to complement its existing Puragen hyaluronic acid device platform under a partnership agreement announced Oct. 30
You may also be interested in...
Mentor Plans Expansion Of Prevelle Dermal Filler Line, Strategic Review
New additions to Mentor's fledgling Prevelle dermal filler portfolio in the U.S. will help grow its facial aesthetic product revenue in the next several years, the company said during a Nov. 5 second-quarter earnings call
Mentor Plans Expansion Of Prevelle Dermal Filler Line, Strategic Review
New additions to Mentor's fledgling Prevelle dermal filler portfolio in the U.S. will help grow its facial aesthetic product revenue in the next several years, the company said during a Nov. 5 second-quarter earnings call
Mentor’s Prevelle Silk
Hyaluronic acid-based dermal filler containing the local anesthetic lidocaine for pain reduction gains FDA market go-ahead for treatment of moderate to severe facial lines, folds and wrinkles. The first in a new line of HA dermal fillers that Mentor is developing with Genzyme under an October 2006 R&D pact, Prevelle Silk will roll out "shortly" on a targeted basis to experienced dermatology and plastic surgery customers, Mentor says. A broader U.S. launch of the product is anticipated by Mentor "later this year," in conjunction with a second lidocaine-containing dermal filler which is under FDA review (1"The Gray Sheet" Nov. 6, 2006, p. 14)